CN1193746C - 作为药用及其它有益用途的取代硝基苯类衍生物 - Google Patents
作为药用及其它有益用途的取代硝基苯类衍生物 Download PDFInfo
- Publication number
- CN1193746C CN1193746C CNB99123684XA CN99123684A CN1193746C CN 1193746 C CN1193746 C CN 1193746C CN B99123684X A CNB99123684X A CN B99123684XA CN 99123684 A CN99123684 A CN 99123684A CN 1193746 C CN1193746 C CN 1193746C
- Authority
- CN
- China
- Prior art keywords
- tert
- butyl benzene
- dimethyl
- disease
- nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims description 23
- 150000005181 nitrobenzenes Chemical class 0.000 title abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 50
- 201000010099 disease Diseases 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims description 102
- 208000017520 skin disease Diseases 0.000 claims description 56
- 206010048768 Dermatosis Diseases 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- NZAWLDGUWOQFQA-UHFFFAOYSA-N 5-tert-butyl-1,3-dimethyl-2-nitrobenzene Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1[N+]([O-])=O NZAWLDGUWOQFQA-UHFFFAOYSA-N 0.000 claims description 23
- ZHFGLQLHVTZCGJ-UHFFFAOYSA-N 3-tert-butyl-1,5-dimethyl-2,4-dinitrobenzene Chemical compound CC1=CC(C)=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O ZHFGLQLHVTZCGJ-UHFFFAOYSA-N 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 22
- 208000024891 symptom Diseases 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- XMWRWTSZNLOZFN-UHFFFAOYSA-N musk xylene Chemical compound CC1=C(N(=O)=O)C(C)=C(N(=O)=O)C(C(C)(C)C)=C1N(=O)=O XMWRWTSZNLOZFN-UHFFFAOYSA-N 0.000 claims description 20
- -1 suspensoid Substances 0.000 claims description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 210000002216 heart Anatomy 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 10
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 9
- 230000036783 anaphylactic response Effects 0.000 claims description 9
- 208000003455 anaphylaxis Diseases 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 210000002784 stomach Anatomy 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- YTZKOQUCBOVLHL-UHFFFAOYSA-N tert-butylbenzene Chemical compound CC(C)(C)C1=CC=CC=C1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 claims description 6
- 206010015150 Erythema Diseases 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 231100000321 erythema Toxicity 0.000 claims description 5
- 201000008827 tuberculosis Diseases 0.000 claims description 5
- AOJWKPQIUREKNP-UHFFFAOYSA-N 1-tert-butyl-3,5-dimethyl-2,4-dinitrobenzene Chemical compound CC1=CC(C(C)(C)C)=C([N+]([O-])=O)C(C)=C1[N+]([O-])=O AOJWKPQIUREKNP-UHFFFAOYSA-N 0.000 claims description 4
- MAXOFIZMGUQLFG-UHFFFAOYSA-N 1-tert-butyl-3,5-dimethyl-2-nitrobenzene Chemical compound CC1=CC(C)=C([N+]([O-])=O)C(C(C)(C)C)=C1 MAXOFIZMGUQLFG-UHFFFAOYSA-N 0.000 claims description 4
- 201000010000 Agranulocytosis Diseases 0.000 claims description 4
- 206010006500 Brucellosis Diseases 0.000 claims description 4
- 201000006082 Chickenpox Diseases 0.000 claims description 4
- 208000007163 Dermatomycoses Diseases 0.000 claims description 4
- 206010018687 Granulocytopenia Diseases 0.000 claims description 4
- 201000005708 Granuloma Annulare Diseases 0.000 claims description 4
- 208000037016 Lymphangiopathies Diseases 0.000 claims description 4
- 201000009053 Neurodermatitis Diseases 0.000 claims description 4
- 206010034038 Parotitis Diseases 0.000 claims description 4
- 208000000474 Poliomyelitis Diseases 0.000 claims description 4
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 4
- 206010039587 Scarlet Fever Diseases 0.000 claims description 4
- 241000605008 Spirillum Species 0.000 claims description 4
- 208000030962 Subcutaneous tissue disease Diseases 0.000 claims description 4
- 206010046980 Varicella Diseases 0.000 claims description 4
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000003929 dermatomycosis Diseases 0.000 claims description 4
- 208000025253 erythroderma desquamativum Diseases 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 230000003780 keratinization Effects 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 208000018555 lymphatic system disease Diseases 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 230000000704 physical effect Effects 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 206010008631 Cholera Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 206010014612 Encephalitis viral Diseases 0.000 claims description 3
- 208000004145 Endometritis Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 206010019799 Hepatitis viral Diseases 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 206010024238 Leptospirosis Diseases 0.000 claims description 3
- 208000005995 Lichenoid Eruptions Diseases 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 201000005702 Pertussis Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 206010035148 Plague Diseases 0.000 claims description 3
- 206010037742 Rabies Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000007893 Salpingitis Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000037386 Typhoid Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010046914 Vaginal infection Diseases 0.000 claims description 3
- 201000008100 Vaginitis Diseases 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 206010003230 arteritis Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 201000001352 cholecystitis Diseases 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 206010013023 diphtheria Diseases 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 208000005963 oophoritis Diseases 0.000 claims description 3
- 201000005737 orchitis Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 208000001297 phlebitis Diseases 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 208000003265 stomatitis Diseases 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 201000008297 typhoid fever Diseases 0.000 claims description 3
- 201000002498 viral encephalitis Diseases 0.000 claims description 3
- 201000001862 viral hepatitis Diseases 0.000 claims description 3
- 208000002003 vulvitis Diseases 0.000 claims description 3
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 206010040400 serum sickness Diseases 0.000 claims description 2
- 201000005113 shigellosis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 230000003405 preventing effect Effects 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 11
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 abstract description 11
- 241001597008 Nomeidae Species 0.000 abstract 2
- 235000013402 health food Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 230000000694 effects Effects 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000005303 weighing Methods 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000037396 body weight Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000001840 Dandruff Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010013663 drug dependence Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 208000032467 Aplastic anaemia Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 239000008896 Opium Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 208000002903 Thalassemia Diseases 0.000 description 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 208000036654 deficiency anemia Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000003701 histiocyte Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229960001027 opium Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 208000008494 pericarditis Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VQWRFIFHRFDBJF-UHFFFAOYSA-N 4-tert-butyl-2,6-dimethyl-1-nitronaphthalene Chemical compound [N+](=O)([O-])C1=C(C=C(C2=CC(=CC=C12)C)C(C)(C)C)C VQWRFIFHRFDBJF-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 208000009084 Cold Injury Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000026137 Soft tissue injury Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000003659 bee venom Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000002595 cold damage Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229960001660 histamine phosphate Drugs 0.000 description 2
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 2
- 230000024278 histolysis Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960002532 methamphetamine hydrochloride Drugs 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- LQNUZADURLCDLV-IDEBNGHGSA-N nitrobenzene Chemical group [O-][N+](=O)[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 LQNUZADURLCDLV-IDEBNGHGSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FZSPYHREEHYLCB-UHFFFAOYSA-N 1-tert-butyl-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(C(C)(C)C)=C1 FZSPYHREEHYLCB-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- VNULEDSHGGKFOJ-UHFFFAOYSA-N 4-tert-butyl-2,6-dimethyl-1,3,5-trinitronaphthalene Chemical compound [O-][N+](=O)C1=C(C)C([N+]([O-])=O)=C(C(C)(C)C)C2=C([N+]([O-])=O)C(C)=CC=C21 VNULEDSHGGKFOJ-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000034598 Caecitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 241000709691 Enterovirus E Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000827798 Hemerocallis citrina Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 206010041290 Soft tissue inflammation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000004387 Typhlitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- FESSJTLQUXXHNF-UHFFFAOYSA-N [Na].[N+](=O)([O-])C1=C(C(=C(C(=C1C)[N+](=O)[O-])C(C)(C)C)[N+](=O)[O-])C Chemical compound [Na].[N+](=O)([O-])C1=C(C(=C(C(=C1C)[N+](=O)[O-])C(C)(C)C)[N+](=O)[O-])C FESSJTLQUXXHNF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001937 intercostal nerve Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及通式I的取代的硝基苯衍生物在医学及功能性保健食品中的用途,含有通式I取代的硝基苯衍生物的药物组合物及预防和/或治疗许多疾病的方法。
Description
本发明涉及通式I的取代的硝基苯衍生物在医学及功能性保健食品中的用途,含有通式I取代的硝基苯衍生物的药物组合物及预防和/或治疗许多疾病的方法。
日本化学杂志(Nippon Kagaku Zaeshi)80,476-86(1953)公开了硝基苯类化合物,但未披露它们的任何用途。
本发明的目的是开发取代的硝基苯衍生物的用途。
本发明人经广泛深入的研究,现已出人意料发现下面通式I的取代的硝基苯衍生物在动物中显示出众多优良的生物活性,例如在免疫调节,抗菌,抗病毒,控制细胞异常增生,心脑血管系统,机械或物理性损伤,血液系统,内分泌系统,药物成瘾,中枢神经系统等方面显示出的优良活性。本发明基于以上发现得以完成。
本发明第一方面涉及的是用于治疗动物中疾病的通式I取代的硝基苯衍生物
其中,A为一,二或三个硝基,且位于苯环1,3,和/或5位;
R为一,二或三个直链或支链C1-6烷基,且位于苯环的2,4和/或6位。
本发明第二方面涉及的是用于治疗动物中疾病的药物组合物,其包括治疗有效量的通式I取代的硝基苯衍生物,药用载体及赋形剂,
其中A为一,二或三个硝基,且位于苯环的1,3和/或5位;
R为一,二或三个直链或支链C1-6烷基,且位于苯环的2,4和/或6位。
本发明再一方面涉及的是通式(I)取代的硝基苯衍生物用于制备功能性保健食品的用途。
其中A为一,二或三个硝基,且位于苯环的1,3和/或5位;
R为一,二或三个直链或支链C1-6烷基,且位于苯环的2,4和/或6位。
本发明再一方面涉及的是通式(I)取代的硝基苯衍生物在制备用于治疗动物中疾病的药物中的用途。
其中A为一,二或三个硝基,且位于苯环的1,3和/或5位;
R为一,二或三个直链或支链C1-6烷基,所代表的C1-6烷基可相同或不同且位于苯环的2,4和/或6位。
本发明再一方面涉及的是一种药物组合物用于制备用于治疗动物中疾病的药物的用途,其中本发明化合物组合物含治疗有效量的通式I取代的硝基苯衍生,及药用载体和赋形剂。
本发明还涉及通式I取代的硝基苯衍生物在制备消毒剂中的用途。
其中A为一,二或三个硝基,且位于苯环的1,3和/或5位;
R为一,二或三个直链或支链C1-6烷基,且位于苯环的2,4和/或6位,其中如存在两个以上(包括两个)R取代基时,则每个R之间可相同或不同。
本发明还涉及通式I取代的硝基苯衍生物在制备化妆品中的用途,
其中A为一,二或三个硝基,且位于苯环的1,3和/或5位;
R为一,二或三个直链或支链C1-6烷基,且位于苯环的2,4和/或6位,其中如存在两个以上(包括两个)R取代基时,则每个R之间可相同或不同。
本发明还涉及治疗动物中疾病的方法,其包括给动物治疗有效量的通式I取代的硝基苯衍生物或含有它的药物组合物。
本发明说明书中所用术语“动物”意指哺乳动物,尤其是人。
本发明说明书中所用术语“直链或支链的C1-6烷基”意指含1-6个碳原子的直链或支链烷基,举例有:甲基,乙基,丙基,异丙基,正丁基,异丁基,仲丁基,叔丁基,戊基,新戊基或己基等。
本发明说明书中所用术语“疾病或症状”意指由免疫失调,细菌,真菌,病毒,神经变性,血液系统失调,细胞异常增殖,内分泌失调,机体组织异常变化,药物成瘾及物理或机械因素等引起的疾病或症状。所述疾病或症状举例有:良性肿瘤,恶性肿瘤,HIV(人体免疫缺陷病毒)引起的AID病,病毒性肝炎,变态反应疾病,支气管炎,哮喘,糖尿病,尿毒症,肾炎,肺结核,痢疾,脊髓灰质炎,水痘,带状疱疹,腮腺炎,霍乱,流行性感冒,猩红热,白喉,百日咳,伤寒,病毒性脑炎,疟疾,黑热病,布氏菌病,狂犬病,鼠疫,炭疽,钩端螺旋体病,再生障碍性贫血,营养缺乏性贫血,溶血性贫血,地中海贫血,血友病,溶血功能障碍,血小板减少性紫癜,粒细胞减少症,白血病,骨髓增殖性疾病,心律失常,风湿性心脏病,高血脂,高胆固醇,心绞痛,高血压,风湿性心辨膜病,心肮炎,心内膜炎,心包炎,心脏神经官能症,动脉粥样硬化,脑血管痉挛,脑中风,脑血栓,周围血管症,类风湿性关节炎,胃炎,胃溃疡,肠炎,视神经炎,眼结膜炎,中耳炎,副鼻窦炎,口腔炎,咽炎,牙龈炎,牙周炎,扁桃体炎,腮腺炎,胆囊炎,膀胱炎,胰腺炎,动脉炎,静脉炎,阴道炎,外阴炎,睾丸炎,输卵管炎,卵巢炎,子宫内膜炎,子宫痉瘤,前列腺炎,软组织炎,骨髓炎,脊髓炎,腹膜炎,盲肠炎,牛皮癣,硬皮症,神经变性疾病如焦虚,抑郁,享廷顿病,帕金森氏症,阿尔茨海默病等,由罂粟碱、吗啡、海洛因、可咔因、冰毒、阿片、杜冷丁等引起的药物成瘾,病毒性皮肤病,球菌性皮肤病,杆菌性皮肤病,真菌性皮肤病,螺旋体皮肤病,动物所致皮肤病,职业性皮肤病,神经机能障碍性皮肤病,应变性皮肤病,物理性皮肤病,光源性皮肤病,过敏性皮肤病,扁平苔藓和苔藓样疹,红斑类皮肤病,红斑鳞屑性皮肤病,水疱性皮肤病,角化性皮肤病,色素障碍性皮肤病,皮肤血管和皮肤淋巴管病,营养和代谢障碍皮肤病,真皮和皮下组织病,网状细胞增多症,皮肤综合症,环状肉芽肿,脓疱性皮肤病,连续性肢端皮炎,宫颈糜烂等生殖器官粘膜病,神经性皮炎,胃、肠、口腔粘膜溃疡性疾病,烧伤,烫伤,冻伤,外伤,骨损伤,软组织损伤,毒蛇咬伤,毒蜂蜇伤等。
根据本发明,优选其中A仅为一个NO2且位于苯环1位,R分别为CH3,C(CH3)3和CH3且位于苯环2,4和6位的式I化合物。
根据本发明,优选其中A为三个NO2且分别位于苯环1,3和5位,R分别为CH3,C(CH3)3和CH3且位于苯环2,4和6位的式I化合物。
根据本发明,优选其中A为二个NO2且分别位于苯环3,5位,R为CH3,C(CH3)3和CH3且分别位于苯环的2,4和6位的式I化合物。
根据本发明,优选其中A为一个NO2且位于苯环的1位,R为C(CH3)3,CH3和CH3且分别位于苯环的2,4和6位的式I化合物。
根据本发明,优选选自下面一组的具体式I化合物:
1,3,5-三硝基-2,6-二甲基-4-叔丁基苯;
1,3-二硝基-2,6-二甲基-4-叔丁基苯;
1,5-二硝基-2,6-二甲基-4-叔丁基苯;
3,5-二硝基-2,6-二甲基-4-叔丁基苯;
1-硝基-2,6-二甲基-4-叔丁基苯;
3-硝基-2,6-二甲基-4-叔丁基苯;
5-硝基-2,6-二甲基-4-叔丁基苯;
1,3,5-三硝基-2,4,6-叔丁基苯;
1,3-二硝基-2,4,6-叔丁基苯;
3,5-二硝基-2,4,6-叔丁基苯;
1,5-二硝基-2,4,6-叔丁基苯;
1-硝基-2,4,6-叔丁基苯;
3-硝基-2,4,6-叔丁基苯;
5-硝基-2,4,6-叔丁基苯;
1,3,5-三硝基-2,4,6-甲基苯;
1,3-二硝基-2,4,6-甲基苯;
3,5-二硝基-2,4,6-甲基苯;
1,5-二硝基-2,4,6-甲基苯;
1-硝基-2,4,6-甲基苯;
3-硝基-2,4,6-甲基苯;
5-硝基-2,4,6-甲基苯;及
1-硝基-2,6-二甲基-4-叔丁基苯。
根据本发明,本发明中在研究中发现本发明的式I化合物可通过对中枢神经系统为主导的机体信息网络调控,选择作用于机体重要活性物质的代谢过程,使机体调节代谢的生理活性物质和对抗内源性和外源性致病因素的活性物质合成加强和细胞分裂加强,从而在直接清除致病因素的同时,积极修复损伤,迅速增强机体本身对致病因素的防御功能,包括屏障作用,免疫监视和识别作用,吞噬和杀伤作用,解毒和清除功能,特异和非特异性免疫功能。具体讲,本发明式I化合物可通过下面途径显示其有益的生物活性。
1.本发明式I化合物能迅速增强机体的特异性免疫和非特异性免疫功能,对正常和异常机体的体液免疫,细胞免疫,网状内皮吞噬功能,及NK细胞的活性均有明显的增强作用,因而可加强机体对细菌、病毒,肿瘤细胞等异物的识别,监视,杀伤,吞噬,清除功能。进一步讲,本发明式I化合物可使敏感动物的中枢淋巴器官的胸腺皮质细胞及骨髓的前驱细胞明显地激活,促进免疫母细胞分裂,增殖,使末稍血流中的淋巴细胞增加并促进淋巴细胞的转化,促浆细胞合成抗体,使巨噬细胞,吞噬细胞能力增强,同时又能保护细胞的稳定性,避免组织溶解,特别是对细胞内寄生的病毒,结核杆菌等致病菌有很好的杀伤作用,对肿瘤细胞有很好杀伤,吞噬,清除作用;及对细菌,真菌,病毒引起的疾病有很好的预防和治疗作用。
2.本发明式I化合物可稳定溶酶体膜,减少水解酶的释出。由于水解酶能使蛋白质分解,使核酸和粘多糖裂解,导致组织细胞破坏和结缔组织分解,并使细胞释放组织胺、5-羟色胺及激肽等,释放的这些物质使血管扩张,血管通透性增加,白细胞聚集,从而引发一系列的炎症反应。因此溶酶体膜的稳定可减少上述炎症的发生,减轻炎症早期渗出、水肿和毛细血管渗出;减轻白细胞、吞噬细胞溶解导致的组织溶解,从而改善红、肿、热、痛等症状;同时也抑制炎症后期纤维母细胞增生,避免肉芽组织生成,防止粘连及瘢痕形成;缓解或消除由于内源性组织胺等物质释放引起的过敏性疾病并起到止痒作用;抑制肥大细胞释放致敏物质,减轻或消除支气管平滑肌痉挛和粘膜水肿,起到止喘止咳作用。由于本发明式I化合物能提高抗体溶酶体膜稳定性,因而能够避免和消除自身免疫性疾病;过敏性疾病,结缔组织增生性疾病等变态反应疾病的发生。
3.本发明式I化合物参与炎症后期的组织修复,促进平滑肌,骨骼肌,真皮,粘膜等组织细胞及神经细胞再生和更新,成纤维母细胞增殖的抑制,从而可抑制肉芽组织的形成,使伤口迅速愈合并避免形成瘢痕以及延缓衰老。
4.本发明式I化合物可通过作用于血红蛋白,血小板,粒细胞促进血红蛋白合成及细胞分裂加强,增强机体造血功能,从而预防和治疗血液疾病,抗疲劳,改善心、脑和其它组织细胞氧供应,改善睡眠,记忆或增智。
5.本发明式I化合物可选择性作用于脑啡肽遗传中心,与阿片受片呈专一性结合,从而具有镇痛作用并可戒断药物成瘾。
6.本发明式I化合物还可有选择地参与神经递质的生物合成与释放,协调胆碱能神经和肾上腺素能神经的功能,调节植物神经和运动神经的功能,例如调节内脏平滑肌,腺体效应器,骨骼肌,血管,心肌的兴奋与抑制,从而有利于机体进行休整和积蓄动量以及调节血质,心率,胃肠道消化功能,机体的内、外分泌等。
7.本发明式I化合物还参与生物催化剂-体内各种生物酶如合成酶,分解酶,工具酶,胰脂肪酶,胰淀粉酶,胰蛋白酶等的代谢以及促进胰岛素的分泌,从而可调节脂肪,糖和蛋白质的代谢,预防和治疗与脂肪、糖和蛋白质的异常代谢有关的疾病或症状如糖尿病,脂肪肝,痛风,动脉粥样硬化等,以及解毒作用如对乙醇中毒,蛇毒及蜂毒的解毒作用。
因此,本发明涉及优选用于预防和/或治疗由免疫功能失调,细菌,真菌,病毒,神经变性,血液系统失调,心脑血管系统失调,细胞异常增殖,内分泌失调,抗体组织异常变化,炎症,药物成瘾及物理或机械因素引起的疾病,损伤或症状的式I化合物,其中A和R如上定义。
更具体讲,根据本发明,本发明优选用于预防和/或治疗人免疫缺陷综合症(AIDS),良性肿瘤,恶性肿瘤,病毒性肝炎,结核,脊髓灰质炎,伤寒,细菌性痢疾,霍乱,流行性感冒,水痘,带状疱疹,腮腺炎,猩红热,白喉,百日咳,乙型脑炎,病毒性脑炎,疟疾,黑热病,狂犬病,鼠疫,炭疽,布氏菌病,钩端螺旋体病的式I化合物及式I化合物在制备用于治疗上述疾病或症状的药物中用途。
根据本发明,本发明优选用于预防和/或治疗心律失常,风湿性心脏病,心绞痛,冠状动脉粥样硬化,高血脂,高胆固醇,高血压,心肌炎,心内膜炎,心包炎,心脏神经官能症,脑血管痉挛,脑血栓,周围血管病的式I化合物及式I化合物在制备用于治疗上述疾病或症状的药物中的用途。
根据本发明,本发明优选用于预防和/或治疗再生障碍性贫血,营养缺乏性贫血,溶血性贫血,地中海贫血,血友病,凝血功能障碍,血小板减少性紫癜,粒细胞减少症,白血病。放、化疗引起的全白细胞减少症的本发明式I化合物及本发明式I化合物在制备用于治疗上述疾病或症状的药物中的用途。
根据本发明,本发明优选用于预防和/或治疗糖尿病,尿毒症,肾炎,肾病综合症的本发明式I化合物及本发明式I化合物在制备用于预防和/或治疗上述疾病或症状的药物。
根据本发明,本发明优选用于预防和/或治疗焦虑,抑郁,享廷顿病,帕金森氏症,阿尔茨海默氏病(老年性痴呆)或早老性痴呆的本发明式I化合物及本发明式I化合物在制备用于预防和/或治疗上述疾病或症状的用途。
根据本发明,本发明优选用于预防和/或治疗骨髓炎,脑炎,视神经炎,眼结膜炎,中耳炎,副鼻窦炎,口腔炎,咽炎,牙龈炎,牙周炎,扁桃腺炎,支气管炎,肺炎,胃肠炎,胆囊炎,膀胱炎,胰腺炎,动脉炎,静脉炎,神经炎,阴道炎,外阴炎,睾丸炎,输卵管炎,子宫内膜炎,卵巢炎,前列腺炎,牛皮癣的本发明式I化合物及式I化合物在制备用于治疗上述疾病或症状的药物中的用途。
根据本发明,本发明优选用于预防和/或治疗系统性红斑狼疮,多发性肌炎,皮肌炎,硬皮症,类风湿性关节炎,风湿性心脏病,风湿性关节炎,溃疡性结肠炎等溃病性粘膜病,天疱疮,过敏性鼻炎,过敏性皮炎,过敏性肠炎,过敏性紫癜,支气管哮喘,血清病,过敏性粒细胞减少症的本发明式I化合物及式I化合物用于制备用于治疗上述疾病或症状的药物中的用途。
根据本发明,本发明优选用于预防和/或治疗病毒性皮肤病,球菌性皮肤病,杆菌性皮肤病,真菌性皮肤病,螺旋体皮肤病,动物所致皮肤病,职业性皮肤病,神经机能障碍性皮肤病,应变性皮肤病,物理性皮肤病,光源性皮肤病,过敏性皮肤病,扁平苔藓和苔癣样疹,红斑类皮肤病,红斑鳞屑性皮肤病,水疱性皮肤病,角化性皮肤病,色素障碍性皮肤病,皮肤血管和皮肤淋巴管病,营养和代谢障碍皮肤病,真皮和皮下组织病,网状细胞增症,皮肤综合症,环状肉芽肿,脓疱性皮肤病,连续性肢端皮炎,宫颈烂等生殖器官粘膜病,神经性皮炎,胃,肠,口腔粘膜溃肠性疾病的本发明式I化合物及式I化合物在制备用于治疗上述疾病和/或症状的药物中的用途。
根据本发明,本发明还优选用于戒断罂粟碱,吗啡,海洛因,可咔因,冰毒,阿片,杜冷丁成瘾的本发明式I化合物及式I化合物在制备用于戒断上述药物成瘾的药物中的用途。
根据本发明,本发明还涉及用于治疗烧伤,烫伤,灼伤,冻伤,创伤,胃损伤,软组织损伤,毒蛇咬伤,毒蜂蜇伤的本发明式I化合物及式I化合物在制备用于治疗上述损伤的药物中的用途。
本发明还涉及包括作为活性成份的至少一种式I化合物及药用载体或赋形剂的药物组合物。本发明药物组合物通常含有0.1-90重量%的式I化合物。根据本发明,本发明药物组合物可按本领域已知的方法制备。根据需要,可将本发明式(I)化合物与一种或多种固体或液体药用载体和/或赋形剂结合,制成可作为人用或兽用的适当的给药形式或剂量形式。
根据本发明,本发明的式(I)化合物或含有它的药物组合物可以单位剂量形式给药,给药途径可为肠道,非肠道或局部,如口服、肌肉、皮下、鼻腔、口腔粘膜、皮肤、静脉、腹膜或直肠等。给药剂型例如片剂、胶囊、滴剂、气雾剂、丸剂、粉剂、溶液剂、混悬剂、乳剂、颗粒剂、软膏、栓剂、冻干粉针剂等,它们可以是普通制剂、缓释制剂、控释制剂及各种微粒给药系统。为了将单位给药剂型制成片剂,可以广泛使用本领域公知的各种载体。关于载体的例子是,例如稀释剂与吸收剂,如淀粉、糊精、硫酸钙、乳糖、甘露醇、蔗糖、氯化钠、葡萄糖、尿素、碳酸钙、白陶土、微晶纤维素、硅酸铝等;湿润剂与粘合剂,如水、甘油、聚乙二醇、乙醇、丙醇、淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、阿拉伯胶、明胶、羧甲基纤维素钠、紫胶、甲基纤维素、磷酸钾、聚乙烯吡咯烷酮等;崩解剂,例如干燥淀粉、海藻酸盐、琼脂粉、褐藻淀粉、碳酸氢钠与枸椽酸、碳酸钙、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基硫酸钠、甲基纤维素、乙基纤维素等;崩解抑制剂,例如蔗糖、三硬脂酸甘油酯、可可脂、氢化油等;吸收促进剂,例如季铵盐、十二烷基硫酸钠等;润滑剂,例如滑石粉、二氧化硅、玉米淀粉、硬脂酸盐、硼酸、液体石蜡、聚乙二醇等。还可以将片剂进一步制成包衣片,例如糖包衣片、薄膜包衣片、肠溶包衣片,或双层片和多层片。为了将给药单元制成丸剂,可以广泛使用本领域公知的各种载体。关于载体的例子是,例如稀释剂与吸收剂,如葡萄糖、乳糖、淀粉、可可脂、氢化植物油、聚乙烯吡咯烷酮、高岭土、滑石粉等;粘合剂,如阿拉伯胶、黄著胶、明胶、乙醇、蜂蜜、液糖、米糊或面糊等;崩解剂,如琼脂粉、干燥淀粉、海藻酸盐、十二烷基硫酸钠、甲基纤维素、乙基纤维素。为了将给药单元制成栓剂,可以广泛使用本领域公知的各种载体。关于载体的例子是,例如聚乙二醇、卵磷脂、可可脂、高级醇、高级醇的酯、明胶、半合成甘油酯等。为了将给药单元制成胶囊,将有效成分式(I)化合物与上述的各种载体混合,将由此得到的混合物置于硬的明胶胶囊或软胶囊中。也可将有效成分式(I)化合物制成微囊剂,混悬于水性介质中形成混悬剂,亦可装入硬胶囊中或制成注射剂应用。为了将给药单元制成注射用制剂,如溶液剂、乳剂、冻干粉针剂和混悬剂,可以使用本领域常用的所有稀释剂,例如,水、乙醇、聚乙二醇、1,3-丙二醇、乙氧基化的异硬脂醇、多氧化的异硬脂醇、聚氧乙烯山梨醇脂肪酸酯等。另外,为了制备等渗注射液,可以向注射用制剂中添加适量的氯化钠、葡萄糖或甘油,此外,还可添加常规的助溶剂、缓冲剂、pH调节剂等。
此外,还需要,也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂、甜味剂或其它材料。
根据本发明,本发明式(I)化合物的给药剂量取决于许多因素,例如所要预防和/或治疗疾病的性质和严重程度,患者或动物的性别、年龄、体重及个体反应,所用的具体化合物,给药途径及给药次数等。本发明式I化合物或含有它的药物组合物可以单一剂量形式或分成几个,例如一,二,三或四个剂量形式给药。
下面的实施例及生物活性实验或临床实验是用来进一步说明本发明,但并不意味着对本发明的任何限制。
一、毒理学试验
1.急性毒性试验。
(1)口服给药
用小鼠,体重20g±2g,雌雄各半。将硝基苯化合物配制成20%的水混悬液,一日3次灌胃给予禁食小白鼠、每次0.3ml,总量18g/kg,相当人日用量的600倍,连续观察7天,未见死亡,未见毒副反应。
(2)注射给药
用小白鼠,体重20g±2g,雌雄各半。将硝基苯化合物配制成2%的注射液。注射给药,每只0.4ml。测得LD50(ip)=18.07+4.52g/kg,LD50(iv)=14.19+2.11g/kg。
2.长期毒性试验
用wistar大鼠,体重86±8g,雌雄各半,共170只。分别灌胃给药。将硝基苯化合物配制成水悬液,剂量分别为0.6,2.0,6g/kg(相当于人日用量的20,70,200倍),每天连续给药六个月。三组动物体重增长与对照组相比,平均体重高于对照组。生物利用率与对照相比明显高于对照组。对外周血象和肝,肾功能及血糖等生化指标均无明显差异。对重要脏器未引起明显的病理改善,表明6g/kg/d时没有毒副反应。
3.遗传毒性试验,传统致畸试验,18个月喂养致癌试验,结果表明硝基苯化合物无明显致畸,致突变,致癌作用。
二、药效学试验
1.观察制备的药品对小鼠和豚鼠止痛,止血,止痒,止咳,止喘作用。
(1)采用小鼠扭体法,观察小鼠灌胃给药后对冰醋酸腹腔注射致痛作用的反应,记录在15分钟内小鼠的扭体次数,比较组间差异,本发明化合物三个剂量组(0.01g/kg,0.02g/kg,0.04g/kg)与对照组比较,均有显著差异,P<0.01,明显减少小鼠扭体次数。试验结果表明:本发明化合物具有明显的止痛作用。
(2)采用豚鼠舔足法,观察本发明化合物局部外用时对磷酸组织胺刺激创面致痒阈的影响。观察记录。三个浓度组(1%,2%,4%)消耗的磷酸组织胺总量(μg)与对照组比较,均有明显差异,P<0.01,试验结果证明本发明化合物致痒阈值明显高于对照组,本发明化合物具有显著的止痒作用。
(3)采用氢氧化胺喷雾致咳法,观察,记录本发明化合物给小鼠灌胃给药后开始出现咳嗽的潜伏期和3分钟内咳嗽次数,与对照组比较,本发明化合物三个剂量(0.01g/kg,0.02g/kg,0.04g/kg)均有明显差异,P<0.05,本发明化合物能明显延长咳嗽潜伏期,减少咳嗽次数,说明本发明化合物具有明显的止咳作用。
(4)采用组织胺喷雾致喘法,观察本发明化合物给小鼠灌胃给药后,记录自喷雾开始至动物发生抽搐翻滚反应的时间,为潜伏期。与对照组比较,三个剂量组(0.02g/kg,0.04g/kg,0.08g/kg)均有显著差异,P<0.01,本发明化合物能明显延长潜伏期,说明具有明显的止喘作用。
(5)采用对小鼠断尾出血法,观察本发明化合物灌胃给药3天后,剪断小鼠尾尖0.5厘米处,血液自行流出后计时,每隔15秒用滤纸吸去血滴一次,直至血液自然停止,计算出血时间,整理数据与对照组比较有显著差异,P<0.01。结果显示本发明化合物三个剂量组(0.01g/kg,0.02g/kg,0.04g/kg)对小鼠出血时间可明显缩短,说明本发明化合物具有明显的止血作用。
2.观察本发明化合物对类风湿性关节炎的预防和治疗作用。
(1)对大鼠佐剂性关节炎的抑制作用。
(2)对其它实验性关节肿胀的抑制作用。
(3)对小鼠腹腔毛细血管通透性的影响。
(4)对大鼠棉球肉芽肿形成的影响。
试验结果证明灌胃给药(0.02g/kg,0.04g/kg,0.08g/kg)三个剂量组对佐剂性关节炎有明显的抑制作用;预防性给药可明显抑制早期炎症反应和再度肿胀;可明显抑制另侧后肢因迟发型超敏反应引起的足肿胀;治疗性给药使注射佐剂侧足肿胀明显消退;使再度肿胀程度明显下降,对另侧迟发型超敏反应性足垫肿胀有明显的抑制作用,对大鼠的耳部红斑及尾部小结节等损害比对照组均有明显的减轻,给药组动物食欲,正常解剖前、后体重无明显差异,对胸腺,脾,肾上腺重量无明显影响。其它实验性关节肿胀的抑制试验,其中大鼠角叉菜胶性足肿胀和大鼠甲醛性足肿胀均有明显的抑制作用并明显抑制棉球肉芽肿的形成,明显降低毛细血管通透性,减少渗出。本试验结果说明本发明化合物对类风湿性关节炎等变态反应疾病有明显的治疗和预防作用。
3.观察本发明化合物对免疫功能的影响。
(1)NK-自然杀伤细胞的活性测定,经口给予小鼠本发明化合物30天,三个剂量组(0.004g/kg,0.04g/kg,0.12g/kg)与对照组比较均有极显著差异,P<0.01,说明本发明化合物对小鼠NK-细胞活性有明显的增强作用。
(2)正常小鼠血清凝集素试验以观察本发明化合物对正常小鼠体液免疫的影响,结果表明。该三个剂量组(0.05g/kg,0.10g/kg,0.20g/kg)均能明显增强血清中抗羊红细胞凝集素值,与对照组比较,具有明显差异,P<0.01,说明本发明化合物有明显促进正常动物体液免疫的作用。
(3)对荷瘤小鼠血清凝集素值影响试验,以观察本发明化合物对荷瘤S-180小鼠体液免疫的影响,结果表示本发明化合物三个剂量组均能明显增强荷瘤S-180小鼠血素中抗羊红细胞凝集素值作用,与对照组比较,有明显的差异,P<0.01,说明本发明化合物可明显提高荷瘤S-180小鼠体液免疫的功能。
(4)对小鼠DTH影响试验以观察本发明化合物对小鼠细胞免疫的影响。结果表示,本发明化合物能明显增加小鼠足趾肿胀差值,与对照组比较有明显差异,P<0.05,说明本发明化合物有明显增强小鼠DTH的作用,说明本发明化合物可明显提高机体细胞免疫功能。
(5)对小鼠碳粒廓清速率的影响试验,以观察本发明化合物对小鼠非特异性免疫的影响。结果表示,本发明化合物三个剂量组碳粒廓清速率均明显高于对照组,吞噬系数α值亦高于对照组,说明本发明化合物对正常小鼠网状内皮吞噬功能有明显增强作用。
4.观察抑制肿瘤生长的作用。
设3个剂理组,0.02g/kg,0.08g/kg,0.16g/kg,与对照组比较。
(1)对小鼠宫颈癌(U14)有明显的抑制作用,平均抑瘤率分别为30.20%,38.07%,46.06%。实验结束时,动物死亡数小于20%,且去瘤后,体重不低于实验前体重,三批实验结果一致。
(2)对小鼠肝癌(肝H2)有明显的抑制生长作用,平均抑瘤率分别为29.53%,38.20%,44.6%。实验结束时动物死亡率小于10%,且去瘤后体重不低于试验前体重。三批实验结果一致。
(3)对小鼠胃癌(Fc)有明显的抑制生长作用,平均抑瘤率分别为30.24%,38.46%,44.05%。实验结束时,动物死亡率小于20%,且去瘤后体重不低于实验前体重。三批实验结果一致。
以上试验表明,具有明显的抑制小鼠移植性肿瘤生长的作用。
5.观察本发明化合物抗疲劳,耐缺氧作用。
设三个剂量组:0.01g/kg,0.02g/kg,0.04g/kg。灌胃给药
(1)观察记录各组小鼠负重1/10体重时的游泳持续时间。比较对照组,均有明显差异,P<0.01。说明本发明化合物具有明显的抗疲劳作用。
(2)观察小鼠耐缺氧时间(S,X±SD)。三个剂量组成与对照组比较均有明显差异,P<0.01。显示本发明化合物具有明显增强小鼠耐缺氧作用。
6.采用常规药效学试验方法,小鼠连续灌胃给药20天,每天0.02g/kg。分2次,在末次给药后24小时取血测Hb,WBC,RBC含量。结果显示用药组与对照组比较有明显的差异。P<0.01,说明本发明化合物可明显增加小鼠外周血WBC、RBC、Hb数。
7.观察本发明化合物对家兔实验性肝损伤、对大鼠急性肝损伤的影响和对大鼠实验性肝硬化、肝细胞再生作用及小鼠肝脏BSP的排泄功能、小鼠TAA肝中毒的保护作用。
研究表明本发明化合物对家兔肝损伤有明显的抑制作用并有明显的降SGPT的作用及有明显的保护细胞作用;抑制肝脂肪样变和肝细胞疏松及嗜酸样变;抑制肝细胞坏死。对急性肝损伤大鼠SGPT及血清胆红素有明显降低作用并明显减轻肝细胞浊肿和脂肪样变及肝细胞核仁消失等病理改变程度。对TAA诱发小鼠急性肝中毒性损伤有明显的抑制SGPT升高和病理改变作用。对CCl所致肝硬化有明显降低羟脯氨酸含量有降低肝总脂含量作用,使病理变化明显减轻。有明显的促进肝细胞再生作用和促进肝脏排泄功能及降低小鼠肝脏BSP滞留量。
8.观察对溃疡性疾病的影响。试验结果表明,0.02g/kg即有明显的抑制应激性溃疡,结扎性溃疡,烧灼性溃疡,利血平性溃疡的作用。对粘膜组织损伤有明显的修复作用。
9.观察对不完全性脑缺血的影响。结扎大鼠双侧颈总动脉后本发明化合物有明显减轻脑血管通透性,控制脑水肿和抑制脑组织病理改变的作用,对软脑膜循环障碍有明显的改善作用。实验显示,有利于脑组织缺血性损伤的恢复作用。
10.观察抗病毒和抗菌作用。结果表明,在感染3和30TCTD5。病毒时,本发明化合物0.01g/kg对流感病毒FM株、肠道病毒E(HO11)和疱疹病毒I型的致细胞病变有明显的抑制作用并对小鼠体内病毒颗粒增殖有明显的抑制作用。本发明化合物抗菌作用试验表明,对所试8种细胞均有明显的抑制作用,包括:流感杆菌,肺炎双球菌,金黄色葡萄球菌,大肠杆菌,绿脓杆菌,结核杆菌,福氏痢疾杆菌,真菌中的酵母菌。
11.临床实验例
1.观察该病理诊断的68例拒绝治疗,仅用支持疗法候死的晚期恶性肿瘤患者症状。体征。实验室检查,抑瘤率在用药前后的对比。
在68例患者中,大肠癌8例,肿癌8例,乳腺癌11例,胃癌9例,食道癌12例,急性淋巴细胞白血病3例,黑色素瘤1例。
用0.01g/kg/d给药,每天3次,连续口服60天。
观察结果:除了1例极晚期患者在用药13天后死亡外,其余67例的恶病质均有极明显的改善。67例患者中伴有疼痛者42例,明显改善39例,其中在服用本发明化合物前,有30例使用依赖性镇痛药物,在服用本发明化合物后,停用依赖性镇痛药物,没有出现明显的戒断症状。伴有咳血、便血者14例,完全改善者14例。黄疸3例,完全改善者3例。转氨酶增高者9例(高于正常值),完全恢复者8例。伴有结核病者4例,治愈4例。伴有吞咽困难者11例,明显缓解者10例。伴有血红蛋白,白细胞,血小板低于正常者68例,明显改善者65例。根据肿瘤体积变化,总缓解率60%。以上对比情况说明本发明化合物在抑制肿瘤生长的同时,明显地提高癌患者的生存质量,改善症状,有效地止痛,止血,止痒,止咳。对转氨酶增高的肝细胞病理改变有明显的治疗作用。对结核病有很好的治疗作用。还能有效地保护造血功能等,及促进食欲,改善焦虑和睡眠。
2.对其它疾病症状的临床观察。
(1)8例支气管哮喘,11例类风湿性关节炎,3例肾病综合症得到明显缓解和控制。24例过敏鼻炎,30例副鼻窦炎,14例红斑狼疮,8例天疱疹,16例过敏性紫癜,14例溃疡性结肠炎,48例口腔溃疡完全治愈。
(2)4例风湿性心辨膜病。12例心律失常,23例高血压病,36例心脏种经官能症得到极明显的控制,2例细菌性心内膜炎,12例心包炎,5例心肌炎完全治愈。
(3)43例皮肤病如病毒性皮肤病,球菌性皮肤病,杆菌性皮肤病,真菌性皮肤病,螺旋体皮肤病,动物所致皮肤病,职业性皮肤病,神经机能障碍性皮肤病,应变性皮肤病,物理性皮肤病,光源性皮肤病,过敏性皮肤病,扁平苔藓和苔癣样疹,红斑类皮肤病,红斑鳞屑性皮肤病,水疱性皮肤病,角化性皮肤病,色素障碍性皮肤病,皮肤血管和皮肤淋巴管病,营养和代谢障碍皮肤病,真皮和皮下组织病,网状细胞增症,皮肤综合症,环状肉芽肿,脓疱性皮肤病,连续性肢端皮炎,宫颈烂等生殖器官粘膜病,神经性皮炎,胃,肠,口腔粘膜溃肠性疾病,完全治愈。
(4)17例慢性肝炎,45例急性肝炎,54例结核病,12例灰质炎,43例痢疾,18例水痘,16例流行性腮腺炎,22例猩红热,26例乙型脑炎,3例黑热病,12例布氏菌病,2例艾滋病均有极明显的疗效,完全治愈。
(5)3例地中海贫血,8例再生障碍性贫血,5例营养缺乏性贫血,13例血小板减少性紫癜,完全治愈。9例急性淋巴细胞白血病明显缓解。
(6)11例重症肌无力,72例神经性头痛,12例脊髓炎,30例肋间神经炎完全治愈。
(7)136例因创伤,烧伤,烫伤,灼伤等因素感染者很快消炎,伤口愈合不留疤痕。
(8)做为功能性保健品,对129例进行抗疲劳抗贫血,抗衰老,改善记忆,促进生长发育,调节血脂,调节血糖,调节血压,改善性功能,观察均具有明显的功效。
10.做为消毒剂试验研究证明0.001%浓度就具有明显的作用。
11.本发明化合物对兔瘟、鸡瘟,马口疫等禽、兽、流行性传染病进行了大规模试用,疗效极其明显,疫情很快得到控制。
12.做为营养剂试验表示,该化合物对植物生长,人,畜动物增重,具有明显的功效。
硝基苯化合物的合成方法
1.取间二甲苯和叔丁醇按1∶3体积置于反应釜内。用适量的三氯化铝做催化剂。用冰水循环冷却。充分搅拌混合,计时反应2小时以上。将反应后的液体缓缓倾入浓盐酸中,体积比例3∶1,颜色澄清透明时,反应完毕。将反应后的液体用氯仿/水进行萃取,充分混匀,静止,将有机层加入碳酸氢钠。反复进行,至pH=6-8为止。蒸馏余液后即得2,6-二甲基-4-叔丁基苯。
2.将2,6-二甲基-4-叔丁基苯溶液置于反应釜内,加入等量乙酸酐,充分搅拌均匀后,缓慢加入硝酸,循环冷却。取反应液样品用T.L.C薄板鉴别反应结束。
3.将反应液加入氯仿萃取,有机层用碳酸钠干燥后过滤,将滤液放置,有白色针状晶体析出,即得产物1-硝基-2,6-二甲基-4-叔丁基苯。分子量207.273,分子式C12H17NO2。
所有化合物溶于有机溶剂,不溶于水。熔点:80-82℃。有挥发油香气,味平。白色成乳白色晶体。其它硝基苯化合物属已有技术。不再重复。
实施例1混悬剂
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯100mg,置于容器中,加入甘油100ml,加热溶解,充分混匀,加入蒸馏水至1000ml刻度,混合均匀,制成0.1%浓度的混悬液。密封装瓶,消毒制成产品。外用药或口服制剂。
实施例2乳剂
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯150mg,置于容器中,加入100ml麻油,加热助溶,充分混匀,加入蒸馏水至1000ml刻度,混合均匀,制成0.15%浓度的乳浊液。密封装瓶,消毒制成产品。外用药或口服制剂。
实施例3外用水溶液
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯200mg,置于容器中,加入100ml乙醇,适量吐温,加热助溶,充分搅拌均匀。加入适量蒸馏水至1000ml处,混合均匀,制成0.2%浓度的水溶液,密封装瓶,消毒制成产品,外用。
实施例4胶囊
称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯300g,黑豆粉300g,葡萄糖140g,白蛋白60g,淀粉200g,研磨过筛,混匀,灌装胶囊,每粒0.2-0.33g内容物。制成口服药品和功能性保健食品。
实施例5注射液
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基萘(钠盐)200mg,置于无菌容器中加入注射用水1000ml溶解,加热助溶,分装成4mg/2ml/支浓度注射液装瓶,密封,消毒制成产品。
实施例6消毒剂
准确称取1-硝基-2,6-二甲基-4-叔丁基或3,5-二硝基-2,6-二甲基-4-叔丁基或1-硝基-2,6-二甲基-4-叔丁基苯100mg,置于容器内,加入适量乙醇和吐温加热助溶。充分混匀后,加入蒸馏水至1000ml刻度混合均匀,制成0.01%浓度的消毒剂。
实施例7外用水剂
准确称取1-硝基-2,6-二甲基-4-叔丁基萘或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯135mg置于容器内,加入乙醇至800ml,过滤,自滤器上添加乙醇使成1000ml,搅匀,即得,制成剂,密封冷藏。
实施例8洗发水
准确称取1-硝基-2,6-二甲基-4-叔丁基萘或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯200mg置于容器中,加入甘油30g,乙醇50ml,摇匀,加入蒸馏水至2000ml刻度,充分混匀即得,制成0.1%浓度的洗发剂。用于秃发和头皮脂溶性皮炎及止痒。
实施例9口服液
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯250mg置于容器中,加入麻油100ml,加热助溶后加入蜂蜜200ml,搅匀,加入蒸馏水至1000ml刻度,混匀制成0.25%浓度的口服液。
实施例10栓剂
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯。100mg,分次加入熔化的半合成脂肪酸甘油酯,迅速搅拌至将凝,注入栓模中,凝固,刮平,取出,包装。
实施例11皮肤用乳剂
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯100mg研细,过筛,置乳钵中,加入花生油研匀,缓缓加入氢氧化钙溶液。研磨至成糊状,加氢氧化钙溶液使成1000ml,制成乳剂,做为皮肤用药。
实施例12软膏
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯100mg研细,过筛,置乳钵中,加甘油研磨溶解后,加入凡士林使成1000g,研匀,制成软膏剂,做为皮肤外用药或皮肤保健制品。
实施例13散剂
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯1000mg。葡萄糖研细,混匀,过筛,制成散剂。
实施例14散剂
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯1000mg,加入200mg滑石粉研匀后,依次加入不得预先研细的硼酸,氧化锌粉末,混匀,再加适量滑石粉至200mg,混匀,制成散剂。
实施例15眼膏
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯200mg,置灭菌乳钵中,加入少量灭过菌的液体石腊研磨,命名成细腻糊状,再分次加入眼膏基质,随加随研匀,使成1000g,无菌分袋,制成眼膏剂。
实施例16滴眼液
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯钠盐50mg,置于灭菌容器中加入注射用水100ml,加热使溶解,加入注射用水至500ml处。分袋成瓶,流通蒸气灭菌30分钟,制成滴眼液。
实施例17滴耳液
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯200mg加入乙醇400ml,加热溶解,滤过,加甘油300ml,搅匀,加蒸馏水至500ml,分装制成滴耳液。
实施例18滴鼻液
准确称取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯200mg,加入40ml乙醇,加热溶解,加入吐温80适量,搅匀,加入蒸馏水至5000ml,充分混匀,制成滴鼻液。
实施例19片剂
按本领域技术人员公知的方法制备。1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯及片剂,其中所述的片剂中按实际需要制成含有1%-2%本发明化合物含量,也可加大或减少,本发明化合物含量。用上述实施例中化合物300g,微晶纤维素200g,300g无水乳糖。200g硬脂酸镁,按公知的技术和装备制成片剂。
实施例20口服液
取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯500mg,加入麻油300ml,加热溶解待用。取黄花100g,瓜子参100g,蒸煮成500ml液体,过滤后,将液体倒入前述待用的溶液中,混合均匀,分装成瓶,蒸气灭菌制成口服液。
实施例21口服营养剂
取1-硝基-2,6-二甲基-4-叔丁基苯或3,5-二硝基-2,6-二甲基-4-叔丁基苯或1,3,5-三硝基-2,6-二甲基-4-叔丁基苯300mg,加入麻油300ml,加热溶解,加入按1∶10稀释的蜂蜜至5000ml,分装成瓶,蒸气灭菌。
实施例22注射剂
一种制备硝基苯化合物钠盐注射剂的方法。
取硝基苯化合物钠盐粉末500mg,加入注射用水500ml,充分均匀,灌装成瓶,蒸气灭菌,研成0.2mg/2ml和0.3mg/3ml针剂。可用于肌肉注射和静脉给药。
Claims (12)
2.权利要求1的用途,其中式I化合物中A仅为一个NO2且位于苯环1位,R分别为CH3,C(CH3)3和CH3且位于苯环2,4和6位。
3.权利要求1的用途,其中式I化合物中A为三个NO2且分别位于苯环1,3和5位,R分别为CH3,C(CH3)3和CH3且位于苯环2,4和6位。
4.权利要求1的用途,其中式I化合物中A为二个NO2且分别位于苯环的3,5位,R为CH3,C(CH3)3和CH3且分别位于苯环的2,4和6位。
5.权利要求1的用途,其中式I化合物中A为一个NO2且位于苯环的1位,R为C(CH3)3,CH3和CH3且分别位于苯环的2,4和6位。
6.权利要求1的用途,其中式I化合物选自:
1,3,5-三硝基-2,6-二甲基-4-叔丁基苯;
1,3-二硝基-2,6-二甲基-4-叔丁基苯;
1,5-二硝基-2,6-二甲基-4-叔丁基苯;
3,5-二硝基-2,6-二甲基-4-叔丁基苯;
1-硝基-2,6-二甲基-4-叔丁基苯;
3-硝基-2,6-二甲基-4-叔丁基苯;
5-硝基-2,6-二甲基-4-叔丁基苯;
1,3,5-三硝基-2,4,6-叔丁基苯;
1,3-二硝基-2,4,6-叔丁基苯;
3,5-二硝基-2,4,6-叔丁基苯;
1,5-二硝基-2,4,6-叔丁基苯;
1-硝基-2,4,6-叔丁基苯;
3-硝基-2,4,6-叔丁基苯;
5-硝基-2,4,6-叔丁基苯;
1,3,5-三硝基-2,4,6-甲基苯;
1,3-二硝基-2,4,6-甲基苯;
3,5-二硝基-2,4,6-甲基苯;
1,5-二硝基-2,4,6-甲基苯;
1-硝基-2,4,6-甲基苯;
3-硝基-2,4,6-甲基苯;
5-硝基-2,4,6-甲基苯;及
1-硝基-2,6-二甲基-4-叔丁基苯。
7.权利要求1的用途,其中所述疾病和/或症状为:
人免疫缺陷综合症,病毒性肝炎,结核,脊髓灰质炎,伤寒,细菌性痢疾,霍乱,流行性感冒,水痘,带状疱疹,腮腺炎,猩红热,白喉,百日咳,乙型脑炎,病毒性脑炎,疟疾,黑热病,狂犬病,鼠疫,炭疽,布氏菌病,钩端螺旋体病。
8.权利要求1的用途,其中所述疾病或症状为:
骨髓炎,脑炎,视神经炎,眼结膜炎,中耳炎,副鼻窦炎,口腔炎,咽炎,牙龈炎,牙周炎,扁桃腺炎,支气管炎,肺炎,胃肠炎,胆囊炎,膀胱炎,胰腺炎,动脉炎,静脉炎,神经炎,阴道炎,外阴炎,睾丸炎,输卵管炎,子宫内膜炎,卵巢炎,前列腺炎,牛皮癣。
9.权利要求1的用途,其中所述疾病或症状为:
系统性红斑狼疮,多发性肌炎,皮肌炎,硬皮症,类风湿性关节炎,风湿性心脏病,风湿性关节炎,溃疡性结肠炎的溃疡性粘膜病,天疱疮,过敏性鼻炎,过敏性皮炎,过敏性肠炎,过敏性紫瘢,支气管哮喘,血清病,过敏性粒细胞减少症。
10.权利要求1的用途,其中所述疾病或症状为:
病毒性皮肤病,球菌性皮肤病,杆菌性皮肤病,真菌性皮肤病,螺旋体皮肤病,动物所致皮肤病,职业性皮肤病,神经机能障碍性皮肤病,应变性皮肤病,物理性皮肤病,光源性皮肤病,过敏性皮肤病,扁平苔藓和苔癣样疹,红斑类皮肤病,红斑鳞屑性皮肤病,水疱性皮肤病,角化性皮肤病,色素障碍性皮肤病,皮肤血管和皮肤淋巴管病,营养和代谢障碍皮肤病,真皮和皮下组织病,网状细胞增症,皮肤综合症,环状肉芽肿,脓疱性皮肤病,连续性肢端皮炎,宫颈糜烂的生殖器官粘膜病,神经性皮炎,胃,肠,口腔粘膜溃疡性疾病。
11.权利要求1的用途,其中所述药物组合物为片剂、胶囊、溶液剂、混悬剂、乳剂、丸剂、颗粒剂、软膏。
12.权利要求1的用途,其中所述药物组合物为注射剂、冻干粉针剂。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB99123684XA CN1193746C (zh) | 1999-11-05 | 1999-11-05 | 作为药用及其它有益用途的取代硝基苯类衍生物 |
EP00972557A EP1232748B1 (en) | 1999-11-05 | 2000-11-03 | Use of substituted nitrobenzene derivatives for the treatment of diseases caused by bacteria, fungi and viruses |
AU11276/01A AU1127601A (en) | 1999-11-05 | 2000-11-03 | Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
PCT/CN2000/000416 WO2001037823A1 (fr) | 1999-11-05 | 2000-11-03 | Produit derive de type nitrobenzene substitue trouvant une application comme medicament ou autres produits efficaces |
DE60027760T DE60027760T2 (de) | 1999-11-05 | 2000-11-03 | Verwendung von substituierten nitrobenzol derivaten zur behandlung von erkrankungen verursacht von bakterien, pilzen und viren |
US11/144,787 US20050228055A1 (en) | 1999-11-05 | 2005-06-06 | Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof |
US12/081,935 US20080227869A1 (en) | 1999-11-05 | 2008-04-23 | Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB99123684XA CN1193746C (zh) | 1999-11-05 | 1999-11-05 | 作为药用及其它有益用途的取代硝基苯类衍生物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510009521 Division CN1679521A (zh) | 1999-11-05 | 1999-11-05 | 取代硝基苯类衍生物在制备产品中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1294911A CN1294911A (zh) | 2001-05-16 |
CN1193746C true CN1193746C (zh) | 2005-03-23 |
Family
ID=5282908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB99123684XA Expired - Lifetime CN1193746C (zh) | 1999-11-05 | 1999-11-05 | 作为药用及其它有益用途的取代硝基苯类衍生物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050228055A1 (zh) |
EP (1) | EP1232748B1 (zh) |
CN (1) | CN1193746C (zh) |
AU (1) | AU1127601A (zh) |
DE (1) | DE60027760T2 (zh) |
WO (1) | WO2001037823A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2571800A1 (en) * | 2005-12-23 | 2007-06-23 | Canadian Blood Services | Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction |
CN102824334A (zh) * | 2012-06-26 | 2012-12-19 | 栾士勋 | 一种抗癌药物 |
CN106727290A (zh) * | 2016-11-28 | 2017-05-31 | 承德雾灵生物医药科技有限公司 | 一种输液针剂及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2023565A (en) * | 1934-02-01 | 1935-12-10 | Du Pont | Manufacture of musk xylene |
CN1056082C (zh) * | 1994-04-08 | 2000-09-06 | 北京市兴大科学系统公司 | 一种抗癌药 |
-
1999
- 1999-11-05 CN CNB99123684XA patent/CN1193746C/zh not_active Expired - Lifetime
-
2000
- 2000-11-03 WO PCT/CN2000/000416 patent/WO2001037823A1/zh active IP Right Grant
- 2000-11-03 EP EP00972557A patent/EP1232748B1/en not_active Expired - Lifetime
- 2000-11-03 DE DE60027760T patent/DE60027760T2/de not_active Expired - Lifetime
- 2000-11-03 AU AU11276/01A patent/AU1127601A/en not_active Abandoned
-
2005
- 2005-06-06 US US11/144,787 patent/US20050228055A1/en not_active Abandoned
-
2008
- 2008-04-23 US US12/081,935 patent/US20080227869A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60027760D1 (de) | 2006-06-08 |
EP1232748A4 (en) | 2004-05-26 |
US20050228055A1 (en) | 2005-10-13 |
CN1294911A (zh) | 2001-05-16 |
EP1232748B1 (en) | 2006-05-03 |
EP1232748A1 (en) | 2002-08-21 |
AU1127601A (en) | 2001-06-04 |
US20080227869A1 (en) | 2008-09-18 |
WO2001037823A1 (fr) | 2001-05-31 |
DE60027760T2 (de) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1564682A (zh) | 谷胱甘肽增强用组合物 | |
CN1481382A (zh) | 异吲哚啉-1-酮葡糖激酶激活剂 | |
CN1468106A (zh) | 糖类吸收抑制剂及其制备方法 | |
CN1161389C (zh) | 银杏叶聚戊烯醇和银杏叶提取物(gbe)的制备方法及其用途 | |
CN112206237A (zh) | 一种含有牛磺酸锌的抗衰老组合物、制备方法及其应用 | |
WO2008029907A1 (fr) | Agent améliorant l'hypertension | |
CN1169774C (zh) | 具有改进水溶性的蜂胶提取物及制备方法和组合物 | |
CN1391477A (zh) | 体力增进剂和糖原畜积促进剂 | |
CN1872278A (zh) | 一种药物组合物 | |
CN1193746C (zh) | 作为药用及其它有益用途的取代硝基苯类衍生物 | |
CN100342862C (zh) | 白藜芦醇低聚茋类化合物及其制法和其药物组合物与用途 | |
CN1902189A (zh) | 来自于植物的β3肾上腺素能受体激动性物质及其利用 | |
CN1308033C (zh) | 减弱阴道酸度及治疗阴道炎的药物及其用途 | |
CN1127950C (zh) | 抗风湿剂 | |
CN1649601A (zh) | 含双果糖酐的组合物及其用途 | |
CN1679521A (zh) | 取代硝基苯类衍生物在制备产品中的用途 | |
CN1400298A (zh) | 从植物果仁中提取的果仁油,其提取方法、药物组合物及应用 | |
CN1861626A (zh) | 一种含有甘草次酸或其衍生物的金属盐类药物及其制备方法 | |
CN1869208A (zh) | 虫草sod的制备以及含虫草sod的保健品 | |
CN111107854B (zh) | 包含β-葡聚糖作为有效成分的宿醉解除用组合物或酒精性肝病预防、改善或治疗用组合物 | |
CN1446225A (zh) | 5′-脱氧-n-(取代氧羰基)-5-氟胞嘧啶及其衍生物、制备方法,和包括该物质作为活性成分的抗癌组合物 | |
CN1695604A (zh) | 防治神经退行疾病、注意力缺陷多动症和抑郁症的药物 | |
CN1772122A (zh) | 一种具有消炎、解毒功效的了哥王制剂 | |
CN100350915C (zh) | 治疗代谢综合症的药物 | |
CN1679940A (zh) | 一种由牛磺酸和保肝药物组成的复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050323 |